The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | EMMA 2017 meeting in Madrid: what to expect
“Heinz Ludwig, MD, from the Wilhelminen Cancer Research Institute, Vienna, Austria, discusses the European Multiple Myeloma Academy (EMMA) meeting. The main focus of this meeting is to provide up-to-date information relevant for managing patients with multiple myeloma (MM) and associated diseases as well as to provide new scientific information along with data on the management of the disease. At the next EMMA meeting held later this year in Madrid, we are to expect more data on daratumumab combinations and other antibody drug combinations. Dr Ludwig mentions that there will be a lymphoma-like therapy in myeloma quite soon, which will help improve treatment outcome tremendously and increase the cure rates. Further, Dr Ludwig notes that it will remain difficult to manage the outcome of patients with ‘high-risk’ features and a lot of effort is required internationally in order to make improvements. Recorded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
“
